What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Ghrelin / GHSR pathway GH-release peptide
Vialdyne primary owner
This Vialdyne page is the primary SEO owner for buyers evaluating Ipamorelin through a pharmacy QA, clinic procurement, or regulated-sourcing workflow. It should answer whether the buyer can request a batch COA, release-test scope, destination-market review, and add-on documentation before moving into pricing or repeat inventory planning.
Overview
Ipamorelin is a five-residue pentapeptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, designed for sharp selectivity at the GHSR (ghrelin / growth-hormone secretagogue receptor). The structural feature that distinguishes it from the older and broader GHRP family (GHRP-2, GHRP-6, Hexarelin) is exactly that selectivity envelope: Ipamorelin engages GHSR while sparing the related receptors that drive cortisol, prolactin, and ACTH release. The absence of cortisol-axis activation is what makes the molecule the cleanest GH-selective option for routine 503A compounding workflows and for any research context where secondary-axis effects would contaminate the readout. For compounding pharmacy buyers, Vialdyne releases Ipamorelin acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The 5-residue sequence is straightforward by SPPS, so the standard batch packet centres on peak-integration RP-HPLC plus ESI-MS identity; LC-MS/MS sequence verification is available on request but is rarely the load-bearing test for a pentapeptide. Most catalogue volume is paired with a GHRH-class agonist (CJC-1295 no-DAC, Sermorelin, or Tesamorelin) in dual-pathway preparations. The canonical CJC-1295 + Ipamorelin pairing is supplied directly as a pre-blended co-lyophilised vial under the cjc-1295-ipamorelin SKU at the standard 5+5 mg fill, with non-standard ratios scoped under change-control. The companion [CJC-1295 + Ipamorelin pharmacology article](/insights/cjc-1295-ipamorelin-blend-pharmacology-guide) covers the dual-pathway rationale and the ratio considerations.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Sterile-filled vials are available with the full release packet (sterility, endotoxin, CCI); loose lyophilized powder ships with sequence verification.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Certificate of Analysis
Published released-batch COAs for Ipamorelin, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →Ipamorelin
VD260428-IPA10116 · 99.53%
VerifiedRequest full COA →Ipamorelin
VD260428-IPA114 · 99.40%
VerifiedRequest full COA →Ipamorelin
VD260428-IPA5115 · 99.45%
Regulatory note
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Selected literature
Frequently asked questions
For a pentapeptide of this size the identity and purity package is straightforward. Ask for an RP-HPLC chromatogram with integrated main-peak area, ESI-MS confirming the expected pentapeptide mass, and either amino-acid analysis or peptide-mapping to verify sequence integrity. Water content and counter-ion (typically acetate or trifluoroacetate) belong on the same certificate, since residual counter-ion affects your net-peptide accounting. Each released lot ships with a COA carrying these results and a documented re-test date, so procurement can align incoming-inspection sampling with the values printed on the batch record rather than re-deriving them.
Because the finished preparation is an injectable, the incoming active needs bacterial-endotoxin and bioburden data before it enters a sterile workflow. For any 503A scope we recommend adding LAL endotoxin per USP <85> and microbial-limits testing per USP <61>/<62> to the same released lot, so the pharmacy is not extrapolating from a different batch. The lyophilised powder should stay sealed at -20 C until the compounding session; reconstitution into bacteriostatic water happens inside the sterile field, and the smallest workable single-use aliquots are drawn immediately to keep thaw exposure at three cycles or fewer.
Related peptides
Modified GRF 1-29 · GHRH analog
29-mer
GHRH 1-29 fragment
GH-axis blend (CJC-1295 no DAC + Ipamorelin)
